
FDA reviews MDMA therapy for PTSD, citing health risks and study flaws
Associated media - Related media Research such as the current MDMA therapy studies has stalled support from various groups and lawmakers in both parties for the treatment of PTSD, a condition that affects millions of Americans, especially military veterans who are at enormous risk of suicide. No new therapies have been approved for PTSD in more than 20 years. “What’s happening is really a paradigm shift for psychiatry,” said David Olson, director of the Institute for Psychedelia and Neurotherapy at UC Davis. “MDMA is an important step for the industry because there is a real lack of effective treatments, and…








